Maternal intrauterine infection/inflammation represents the major etiology of preterm delivery and the leading cause of neonatal mortality and morbidity. The aim of this study was to investigate the anti-inflammatory properties of thioredoxin-1 in vivo and its potential ability to attenuate the rate of inflammation-induced preterm delivery. Methods: Two intraperitoneal injections of lipopolysaccharide from Escherichia coli were administered in pregnant mice on gestational day 15, with a 3-h interval between the injections. From either 1 h before or 1 h after the first lipopolysaccharide injection, mice received three intravenous injections of either recombinant human thioredoxin-1, ovalbumin, or vehicle, with a 3-h interval between injections. results: Intraperitoneal injection of lipopolysaccharide induced a rise of tumor necrosis factor-α, interferon-γ, monocyte chemotactic protein 1, and interleukin-6 in maternal serum levels and provoked preterm delivery. Recombinant human thoredoxin-1 prevented the rise in these proinflammatory cytokine levels. After the inflammatory challenge, placentas exhibited severe maternal vascular dilatation and congestion and a marked decidual neutrophil activation. These placental pathological findings were ameliorated by recombinant human thioredoxin-1, and the rate of inflammation-induced preterm delivery was attenuated. conclusion: Thioredoxin-1 may thus represent a novel effective treatment to delay inflammation-induced preterm delivery.
t he estimated number of preterm births (defined as birth before gestational week 37) worldwide was 15 million in 2010 (11.1%) (1) . Preterm birth is the most frequent cause of infant mortality and leads to one million deaths per year. Premature infants face increased risk of neonatal complications, such as intraventricular hemorrhage, bronchopulmonary dysplasia, retinopathy, and necrotizing enterocolitis as well as increased risk of adult-onset obesity, diabetes, and hypertension (2, 3) .
Intrauterine infection or inflammation caused by various bacteria, including Escherichia coli, Gardnerella vaginalis, anaerobic bacteria, and genital mycoplasmas, can lead to preterm birth (4, 5) . Animal models of bacterial componentinduced preterm birth have been established (6, 7) .
Thioredoxin-1 (TRX), originally cloned as a soluble factor called adult T-cell leukemia-derived factor (8) , is one of the most important molecules controlling the redox regulation system and contains a redox-active disulfide/dithiol within the conserved active site sequence Cys 32 -Gly-Pro-Cys 35 (ref. (9)). TRX has a pivotal role in scavenging reactive oxygen species (ROS) with peroxiredoxins, and thus, it prevents apoptosis of various cells (10) . Moreover, circulating TRX inhibits neutrophil infiltration into the sites of inflammation by blocking the adhesion of lipopolysaccharide (LPS)-stimulated neutrophils on endothelial cells (11) . Overexpression of human TRX in transgenic mice induced resistance to harmful conditions, including thioacetamide-or LPS-induced acute hepatitis (12) , and proinflammatory cytokine-or bleomycin-induced lung injury (13) . These findings suggest that TRX has protective effects on various diseases, possibly due to its antioxidative and anti-inflammatory actions. However, little is known about the role of TRX in intrauterine inflammation.
In the present study, we investigated the ability of TRX to attenuate the rate of preterm delivery in vivo in a murine model of intrauterine inflammation. We found that intravenous administration of recombinant human thioredoxin-1 (rhTRX) reduced the rate of inflammation-induced preterm delivery by suppressing maternal proinflammatory cytokine production and placental pathological changes, including vascular dilatation and congestion, and decidual neutrophil infiltration.
RESULTS

Prophylactic Effect of TRX on Inflammation-Induced Preterm Delivery
First, to investigate whether exogenous TRX has prophylactic efficacy in preterm delivery, we intravenously administered rhTRX to LPS-treated pregnant mice using the protocols described (Figure 1a) . In the prophylactic protocol, intraperitoneal (i.p.) injection of LPS provoked preterm delivery in 15 of 16 treated animals (94%). No maternal mortality was observed. The rates of preterm delivery in the phosphate-buffered saline (PBS)-treated group and ovalbumin (OVA)-treated group were 100% (10/10) and 89% (8/9), respectively. Treatment with rhTRX 1 h before the LPS injection significantly reduced the rate of preterm delivery (40 vs. 94%; P < 0.01), whereas the rates of preterm delivery did not change after treatment with PBS or OVA ( Table 1) .
Inhibition of Inflammation-Induced Histological Changes in the Placenta by TRX
To investigate whether prophylactic administration of rhTRX ameliorates placental inflammation in LPS-induced preterm delivery, sections of uteroplacental tissue from the four groups of animals (untreated, LPS-treated, LPS-treated with either PBS or rhTRX) were mounted. Histological aspects were assessed using hematoxylin and eosin stain, and the extent of inflammatory cell infiltration was assessed using neutrophil immunohistochemistry. Histological analysis of placental sections from LPS-treated mice revealed maternal blood congestion and vascular dilatation in the placental labyrinth ( Figure 2) and neutrophil activation which was demonstrated by deformed or adhered neutrophils at around decidual vessels from maternal blood sinuses (Figure 3a) . In contrast, TRXtreated animals before LPS injection exhibited reduced maternal blood congestion and vascular dilatation in the labyrinth (Figure 2d) . Furthermore, the number of deformed or adhered activated neutrophil in the decidua was decreased in the TRXtreated group (LPS-TRX) compared with the LPS-treated 
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Articles group, although no changes in total neutrophil counts in the decidua were observed between these two groups ( Figure 3b ).
Decrease in Serum Levels of Inflammation-Induced Cytokines by TRX
To determine whether the onset of preterm labor in LPStreated animals was concomitant to a maternal systemic or intrauterine inflammation and whether this phenomenon was prevented in the presence of prophylactic TRX, the levels of cytokines (interleukin (IL)-12, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), monocyte chemotactic protein 1 (MCP-1), IL-10, and IL-6) in maternal sera were measured. As depicted in Figure 4 , i.p. injection of LPS induced a significant increase in TNF-α, IFN-γ, MCP-1, and IL-6 levels in the maternal serum compared with untreated control animals 6 h after the first LPS injection, demonstrating that a systemic inflammation was mounted against LPS in these animals. LPS i.p. injection did not significantly affect the levels of IL-12 and IL-10 in the maternal serum. The injection of TRX significantly diminished the increase in TNF-α, IFN-γ, MCP-1, and IL-6 levels in maternal serum of LPS-treated animals (P < 0.01) while not significantly affecting IL-12 and IL-10 levels ( Figure 4 ).
No Change in Serum Levels of Macrophage Migration Inhibitory Factor After Prophylactic TRX Administration During Intrauterine Inflammation
Serum macrophage migration inhibitory factor (MIF) levels were significantly higher in pregnant mice than in nonpregnant mice (P < 0.01) and in the LPS-induced preterm delivery mouse model than in untreated normal pregnant mice (P < 0.05). High serum MIF levels were observed in all three LPS-treated groups (LPS, LPS-PBS, and LPS-TRX), without significant difference between the three groups ( Figure 5 ).
Therapeutic Effect of TRX on Inflammation-Induced Preterm Delivery
To investigate whether exogenous TRX has therapeutic efficacy in preterm delivery, rhTRX was intravenously administered to LPS-treated pregnant mice using the therapeutic protocol (Figure 1b) . I.p. injection of LPS provoked preterm delivery in 15 of 22 treated animals (68%). The rates of preterm delivery in the PBS-treated group and the TRX-treated group were 68% (23/34) and 41% (14/34), respectively. The rate of preterm delivery was significantly lower in the TRX-treated group than in the PBS-treated group in the therapeutic protocol (41 vs. 68%; P < 0.05) ( Table 2) .
Inhibitory Effect of TRX on LPS-Induced ROS Production in the Mouse Macrophages
To elucidate the inhibitory effect of TRX on ROS production, ROS in a primary culture of mouse peritoneal macrophages were measured using methods previously reported (14) . LPS (2 μg/ml) induced ROS production in mice peritoneal macrophages while TRX (20 μg/ml) significantly decreased the ROS derived fluorescence after LPS treatment (Figure 6a,b) . TRX revealed LPS-induced ROS-scavenging properties in vitro.
DISCUSSION
In the present study, we report for the first time that TRX blocks systemic and placental inflammation in vivo and attenuates the rate of preterm delivery in a mouse model. Preterm delivery is a leading cause of neonatal mortality and morbidity. To date, several tocolytic agents, such as the β-adrenergic Articles Namba et al.
agonist ritodrine and magnesium sulfate, have been used to prolong pregnancy (15) . An analysis of 36 randomized controlled trials demonstrated that prenatal administration of progesterone prevented preterm birth (16) . Nonetheless, the incidence of preterm birth continues to rise (17, 18) .
Evidence from animal models of preterm birth also strongly suggest that several molecules, including phosphodiesterase-4 inhibitor, cyclopentenone prostaglandin, anti-TNF-α, matrix metalloproteinase inhibitor, and folic acid, may be useful to treat inflammation-induced preterm labor (19) (20) (21) (22) (23) . In addition to these agents, antioxidants are believed to represent a promising treatment option, not only for preterm birth (7, 14, 24) but also for neonatal disorders, bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and periventricular leukomalacia (25) . We showed that TRX is one of the potential agents for intrauterine infection/inflammation by its antioxidant and anti-inflammatory properties.
The main concern related to therapeutic agents for preterm birth is the potential toxicity in the developing fetus. TRX is naturally produced and ubiquitously expressed in normal human tissues or cells. From a safety standpoint, we used rhTRX for preventing preterm birth of the mouse model in this study and showed that rhTRX was effective in a prophylactic protocol as well as a therapeutic protocol against LPS. The preterm delivery rates of LPS-treated mice in prophylactic and therapeutic protocol were 94 and 68%, respectively. LPS-induced preterm delivery rate between prophylactic and therapeutic protocols was not significant (P = 0.1, Fisher's exact test).
In the human chorioamnionitis placenta, neutrophils first accumulate in the intervillous space immediately below the chorionic plate, which forms the roof of this space. The neutrophils in the roof of the intervillous space later extend upwards into the chorionic plate and reach the amnion of the fetus. At this stage, the neutrophils are purely maternal in origin in humans, being derived from maternal blood in the intervillous space (5). In placentas from rhTRX-treated mice, the administration of rhTRX appeared to prevent neutrophil activation into decidual tissue through the endothelial cells lining the blood vessels. The inhibitory effect of rhTRX on neutrophil activation appears to have an important role in attenuating the rate of preterm birth. The administration of rhTRX ameliorated severe maternal vascular dilatation and congestion in the placental labyrinth, which was the most consistent finding in LPSinduced preterm delivery model (26) . Majority of the dilated Articles vessels were maternal, as judged from the paucity of nucleated fetal blood cells. Rounioja et al. (27) suggested that the fetal vessels in the labyrinth were severely engorged due to external compression by edematous extravascular tissue, resulting in an inappropriate increase in placental vascular resistance. The increased production of proinflammatory mediators, such as TNF-α and IL-1, together with other inflammatory agents may lead to increased permeability in gestational tissues, resulting in acute congestion (26) . Our data showed that rhTRX suppressed LPS-induced production of systematic TNF-α, IFN-γ, MCP-1, and IL-6 in sera from pregnant mice. TRX may improve maternal and fetal hemodynamic deterioration, which avoids placental congestion, in part by suppressing proinflammatory cytokines.
One of the mechanisms of suppression of LPS-induced cytokine production by TRX is that TRX directly associates with MIF and inhibits its expression and release (28) . MIF has been classified as a powerful cytokine, capable of inducing TNF-α, IL-1β, IL-6, and IL-8, and amplifying LPS-driven cytokine responses (29) . However, in the present study, we observed no difference in MIF serum levels between rhTRX-treated and untreated pregnant mice.
In conclusion, we have demonstrated that rhTRX ameliorates the rate of preterm delivery by its inhibitory effects on maternal systemic and placental inflammation. Considering the potent protective role observed in this study, rhTRX may represent a new therapeutic molecule for treatment of preterm delivery.
METHODS
Animals
Animal protocols were approved by the Institutional Animal Care and Use Committee of Osaka Medical Center and Research Institute for Maternal and Child Health. C3H/HeN female mice and B6D2F1 male mice were purchased from Charles River Laboratories (Yokohama, Japan). All animal experiments were performed in accordance with the guidelines of Osaka Medical Center and Research Institute for Maternal and Child Health for animal and recombinant DNA experiments. All mice were maintained under conventional housing conditions and had free access to commercial food (Oriental Yeast, Tokyo, Japan) and water.
Mouse Model of Inflammation-Induced Preterm Delivery
C3H/HeN female mice (9-14 wk old) were pair-mated with male B6D2F1 mice. The day on which a vaginal plug was detected was designated as gestational day 0. All untreated pregnant mice delivered pups at gestational day 19 or 20. Animals in the preterm delivery models were treated according to the method reported by Kaga et al. (30) . On gestational day 15, two i.p. injections of LPS (200 μg/kg) from E. coli (serotype O55: B5; Sigma-Aldrich Corporation, St. Louis, MO) dissolved in 10 ml/kg of sterile saline were administered, with a 3-h interval between the injections (at 0 and 3 h).
rhTRX Administration rhTRX was supplied by Redox Bio Science (Kyoto, Japan). The quality and purity of the rhTRX used for the present study were approved by Pharmaceuticals and Medical Devices Agency in Japan, which is equivalent to the Food and Drug Administration in the United States. Its safety and kinetics were established in preclinical studies using animal models (31) .
To investigate the effects of TRX on maternal systemic and placental inflammation, two protocols were designed using the LPS-induced preterm delivery model. From 1 h before the first LPS injection, mice received three i.v. tail vein injections of PBS (10 ml/kg), containing either rhTRX (2 mg/kg), OVA (Albumin, Egg, Nacalai tesque, Kyoto: OVA; 2 mg/kg), or vehicle, with a 3-h interval between injections (at −1, 2, and 5 h). The assessment of the presence or absence of delivery was performed in the early morning and the late afternoon every day throughout the experimental period. Delivery at gestational day <19 was defined as preterm and delivery at gestational day 19 or >19 was defined as full-term (prophylactic protocol, Figure 1a) . From 1 h after the first LPS injection, mice received three i.v. injections of 10 ml/kg of PBS containing either rhTRX (2 mg/kg) or the vehicle, with a 3 h interval between injections (at 1, 4, and 7 h) (therapeutic protocol, Figure 1b) .
Histochemistry and Immunohistochemistry
Mice were euthanized by carbon dioxide inhalation 6 h after the first LPS injection in prophylactic protocol. Intact uteroplacental units and fetuses were harvested, fixed in 10% formalin, and embedded in paraffin (sampling protocol). Placental structures were identified on 3-μm paraffin slides by hematoxylin and eosin stain (Mayer's hematoxylin and 1% Eosin Y Solution; Muto Pure Chemicals, Tokyo, Japan). For placental immunohistochemistry, slides were deparaffinized through three rinses in xylene (Wako Pure Chemical Industries, Osaka, Japan) and rehydrated through graded ethanol to deionized water. To detect neutrophils, a rat monoclonal antibody (NIMP-R14) directed against the neutrophil membrane (Abcam, Cambridge, UK) diluted to 1/500 in PBS was used. After antigen retrieval and blocking endogenous peroxidase activity, incubation was processed overnight at 4 °C. After successive rinses, immunoreactivity was detected using peroxidaselabeled affinity-purified antibody to rat immunoglobulin G (KPL Europe, Guildford, UK) or Takara POD conjugate anti-Rat for mouse tissue (Takara Bio, Otsu, Japan). Color development was performed using diaminobenzidin solution (Wako Pure Chemical Industries, Osaka, Japan), and tissue sections were counterstained with hematoxylin (Muto Pure Chemicals, Tokyo, Japan). Decidual large vessel neutrophils were then counted in each 4 mice placentas obtained from LPS treatment or prophylactic protocol treatment. Observed neutrophils were classified into two groups, inactivated neutrophils; sole and intravenously located with normal structure, and activated neutrophils; aggregated and attached to endothelial cells with deformed shape. At least 4 microscopic photographs were taken in each placenta. Total neutrophils and activated neutrophil were counted in the same magnified microscopic field (an objective lens at ×20).
Cytokine Measurement in Maternal Serum
Mice were euthanized by carbon dioxide inhalation 6 h after the first LPS injection in prophylactic protocol. The maternal blood samples were allowed to coagulate overnight at room temperature and subsequently centrifuged at 10,000 × g for 20 min at 4 °C. The serum was carefully removed and stored at −20 °C until used. Mouse IL-12, TNF-α, IFN-γ, MCP-1, IL-10, and IL-6 levels were determined in maternal serum using a cytometric bead array kit (BD Cytometric Bead Array Mouse Inflammation Kit; BD Biosciences, San Diego, CA) according to the manufacturer's instructions. In brief, 50 μl of mouse inflammation capture bead suspension and 50 μl of phycoerythrin detection reagent were added to equal amounts of the sample or standard dilution and incubated for 2 h at room temperature in the dark. Subsequently, samples were washed by adding 1 ml of wash buffer and centrifuging at 200 × g at room temperature for 5 min. The supernatant was discarded and 300 μl of wash buffer were added. Samples were analyzed on a BD FACScan Flow Cytometer (BD Biosciences) according to the manufacturer's instructions.
The serum levels of mouse MIF were determined by the mouse MIF enzyme-linked immunosorbent assay kit (Sapporo Immuno Diagnostic Laboratory, Sapporo, Japan).
ROS production assay
ROS production assay in cultured peritoneal macrophages of C57BL/6J mice (Japan SLC, Inc., Shizuoka, Japan) were performed according to our previous report (14) with slight modification. In brief, 1 ml of 3% sterilized fluid thioglycollate medium II (Eiken Chemical, Tokyo, Japan) was injected into the intraperitoneal cavities of 8-12-wk-old nonpregnant female mice. Three days later, the refluxed intraperitoneal fluid was collected, and macrophages were kept in the RPMI 1640 medium (Sigma) containing 10% fetal calf serum, 100 U/ml of penicillin G (Sigma), and 100 mg/ml of streptomycin (Sigma). Macrophages were plated on 12-well plate and incubated with 2 μg/ml of LPS (E coli O55:B5; Sigma) for 1h at 37 °C and incubated with 20 μg/ml of TRX for 6 h at 37 °C. Next, the cells were incubated for an additional 30 min at 37 °C and stained with 5 μmol/lCellROX reagent (Life Technologies). After incubation, the cells were washed three times with PBS. ROS production was expressed in reactive fluorescence units by using a fluorescence microscope (Eclipse Ti; Nikon, Tokyo, Japan) with a filter for green fluorescent protein (86009; Chroma Technology, Bellow Falls, VT) was used, and images were acquired using DS-Qi2 (Nikon). The images were analyzed using NIS Elements software (Nikon). For the quantification of ROS production in each study groups, mean fluorescence units were calculated from three independent experiments of the fluorescence microscopic observations of at least 400 cells.
Data Analysis
Statistical analysis was performed using the software Statistical Package for the Social Sciences (SPSS) 11.0 for Windows (SPSS, Chicago, IL). The results of each experiment were expressed as the incidence and rate of preterm and term deliveries and as a box-and-whisker representation (the median, quartile, and range). The differences between each group were analyzed by Fisher's exact test (Table 1) , chi-square test (Table 2 ), Student's t-test (Figure 3) , Mann-Whitney U-test (Figures  4 and 5) , or Tukey's post-hoc test with one-way ANOVA (Figure 6) . The difference was considered to be statistically significant at P < 0.05.
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